movement

Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain. Seltorexant is a high-affinity and selective orexin-2 receptor antagonist (pKi: 8.0 and 8.1 for human and rat OX2R).

Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET).

Taminadenant is an adenosine receptor antagonist.

Fluphenazine decanoate is dopamine D2 receptor blocke,and is a long-acting phenothiazine neuroleptic that used to treat schizophrenia.

RWJ-51204 is a selective adenosine A2A receptor antagonist and a partial agonist of GABA(A) receptor (IC50: 0.2-2 nM). It has neuroprotective and movement-improving effects and can be used in research related to Parkinson's disease.

Anpirtoline hydrochloride (D-16949 hydrochloride) is a novel and potent 5-HT1B receptor agonist and 5-HT3 receptor antagonist with anti-injurious, analgesic, and antidepressant activity, and is used in the study of movement disorders.

SB 243213 is an orally available and selective 5-HT2C receptor antagonist.SB 243213 has anxiolytic and antidepressant activity and is used in schizophrenia and movement disorders.

Sarizotan 2HCl is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinsonian movement disorders.

Binospirone (MDL 73005EF) is a 5-HT1A receptor agonist with anxiolytic activity used in the study of glaucoma and movement disorders associated with neurologic dysfunction.

Tetrabenazine (Ro 1-9569) is a former antipsychotic drug used to treat various movement disorders. It inhibits neurotransmitter uptake into adrenergic storage vesicles and serves as a high-affinity label for the vesicle transport system.

Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.

20-HC-Me-Pyrrolidine is a potent Aster protein inhibitor with IC50=0.06~0.71 μm for Aster-A, Aster-B, and Aster-C that blocks the ability of Aster proteins to bind and transfer cholesterol, including inhibiting the movement of LDL cholesterol to the endoplasmic reticulum.

NO 711（NNC-711 free acid） is a potent and selective inhibitor of GABA transporter 1 (GAT-1), which increases GABAergic transmission, enhances non-rapid eye movement sleep, and prevents and treats paclitaxel-induced neuropathic pain.

CK-666 is a cell-permeable inhibitor of the actin-related protein Arp2/3 complex, binding to and stabilizing its inactive state, thereby preventing the movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) configuration.

Tetrabenazine-D6 is a deuterated derivative of tetrabenazine that can be used in research related to Huntington’s disease and other hyperkinetic disorders.

Eliprodil (SL-820715)(SL-820715), a non-competitive NR2B-NMDA receptor antagonist(IC50: 1 uM), less effective for NR2A- and NR2C-containing receptors(IC50> 100 uM). It has been used in trials studying the treatment of Parkinson Disease and Movement Disorders.

Phalloidin is a bicyclic heptapeptide found in Amanita mushrooms that binds specifically to F-actin, stabilizing the microfilaments and inhibiting their depolymerization, thereby disrupting cell movement and growth. Phalloidin itself is not fluorescent; it is often conjugated with fluorescent molecules for F-actin staining and is widely used in research such as cytoskeletal imaging and cerebral vascular labeling.

4-Acetyl-N-methylaniline-13C-D3 is an isotopically labeled version of 4-Acetyl-N-methylaniline, featuring both 13C and tritium (D3) markers. Compounds marked with stable or radioactive isotopes are utilized in metabolic analysis to precisely trace and quantify the movement of individual atoms.

PXT-012253 is a positron emission tomography (PET) ligand targeting mGluR4, designed to bind to its allosteric sites. This compound is useful for research related to Parkinson's disease and levodopa-induced movement disorders.

SDZ 210-086, an oral muscarinic agonist, has been shown to reduce rapid eye movement (REM) latency, increase the percentage of REM sleep, and extend the total duration of REM sleep. Additionally, SDZ 210-086 significantly decreases the time spent in slow-wave sleep.

RDS-127 induces biphasic dose-related changes in spontaneous locomotor activity in rats, similar to the reported effects of APO. Compared to APO, RDS-127 demonstrates a more potent stimulation of movement, with an efficacy that is tripled and lasts four times longer. In terms of selectivity, RDS-127 clearly outperforms APO, showing a preference for activating DA autoreceptors in the nigrostriatal pathway rather than postsynaptic DA receptors.

4-Hydroxy MET (4-HO-MET) is a tryptamine-based new psychoactive substance (NPS), structurally similar to the endogenous neurotransmitter serotonin. It has hallucinogenic properties that affect mood, movement, and cognitive functions.

Ebio3 is a selective potassium ion channel (KCNQ2) inhibitor with an IC50 of 1.2 nM. It binds to the KCNQ2 channel via its hydrophobic tail, causing the inward movement of the S6 helix, which results in the closure of the internal gate. The inhibitory effect of Ebio3 is equally effective on pathogenic KCNQ2 mutants, such as R75C and I238L, reducing their outward current by approximately 80%. Ebio3 holds potential for research in neurological disorders like epilepsy.

HPH-15 is an anti-cell migration compound that inhibits cell movement by binding to hnRNP U or suppressing TGF-β. Additionally, it prevents epithelial-to-mesenchymal transition (EMT). HPH-15 holds potential for research in areas such as anti-tumor metastasis and anti-fibrosis.